CTLA4 and melanoma: Monoclonal antibodies (mAbs) to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) protein, two T cell-inhibitory checkpoint receptors with independent mechanisms of action, have demonstrated improvement in overall survival in advanced melanoma patients [1–3].